GSK789
GSK789 is a selective inhibitor of BET BD1. GSK789 inhibits the growth of leukemia cell lines. GSK789 inhibits LPS-stimulated production of MCP-1, TNFα and IL-6 in human whole blood. GSK789 exhibits antiproliferative, anti-inflammatory and immunomodulatory activities. GSK789 can be used in research related to cancers such as leukemia, as well as inflammatory and immune diseases.
For research use only. We do not sell to patients.
- CAS No.: 2540591-06-6
- Formula: C26H33N5O3
- Molecular Weight:463.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
390 nM
Compound: 42, GSK789, Single enantiomer
|
Antiproliferative activity against human HL-60 cells after 72 hrs by cell titer glo assay
Antiproliferative activity against human HL-60 cells after 72 hrs by cell titer glo assay
|
[PMID: 32691589] |
| MV4-11 | IC50 |
124.6 nM
Compound: 42, GSK789, Single enantiomer
|
Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer glo assay
Antiproliferative activity against human MV4-11 cells after 72 hrs by cell titer glo assay
|
[PMID: 32691589] |
| THP-1 | IC50 |
158 nM
Compound: 42, GSK789, Single enantiomer
|
Antiproliferative activity against human THP-1 cells after 72 hrs by cell titer glo assay
Antiproliferative activity against human THP-1 cells after 72 hrs by cell titer glo assay
|
[PMID: 32691589] |
In Vitro
GSK789 (Compound 42) binds efficiently to BRD2 BD1, BRD3 BD1, BRD4 BD1 and BRDT BD1 (pKd = 7.7-8.4)[1].
GSK789 potently inhibits BRD4 BD1 (pIC50 = 7.5) and inhibits BRD4 BD2 (pIC50 = 4.5) in TR-FRET assays[1].
GSK789 (0.001-100 μM; 3 days) potently inhibits the growth of MV-4-11, HL60 and THP-1 leukemia cell lines, with IC50 values of 124.6 nM, 390.0 nM and 158.0 nM, respectively; complete inhibition is achieved at the concentration with the weakest binding affinity to the BET BD2 domain[1].
GSK789 potently inhibits the production of LPS (HY-D1056)-stimulated MCP-1 (IC50 = 0.67 μM), TNFα (IC50 = 0.87 μM), and IL-6 (IC50 = 3.55 μM) in human whole blood[1].
GSK789 (0.3-10 μM) exhibits a phenotypic fingerprint unique to BD1-selective BET inhibitors in the BioMAP Diversity PLUS platform, and exerts antiproliferative, anti-inflammatory and immunomodulatory effects in human primary cell assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human leukemia cell lines (MV-4-11, HL60, THP-1)
-
Concentration:0.001, 0.01, 0.1, 1, 10, 100 μM
-
Incubation Time:3 days
-
Result:Inhibited cell growth with an IC50 of 124.6 nM in MV-4-11 cells.
Inhibited cell growth with an IC50 of 390.0 nM in HL60 cells.
Inhibited cell growth with an IC50 of 158.0 nM in THP-1 cells.
Achieved full inhibition at concentrations where BD2 engagement was minimal.
Chemical Information
-
CAS No. 2540591-06-6
-
Molecular Weight 463.57
-
Formula C26H33N5O3
-
SMILES
O=C([C@@H]1CN(C)CC[C@H]1NC2=C3NC(C(C)=CC3=C(C4=CC=CO4)C=N2)=O)NC5CCCCC5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)